

*What is claimed is:*

1. A method of treating Parkinson's Disease, comprising administering to a patient in need thereof a first composition comprising safinamide, a safinamide derivative or a MAO-B inhibitor and a second composition comprising at least one Parkinson's Disease agent, in an amount effective to treat said Parkinson's Disease in said patient.
2. The method of claim 1, wherein the first composition is safinamide.
3. The method of claim 1, wherein the first composition is a safinamide derivative.
4. The method of claim 3, wherein the safinamide derivative is selected from the group consisting of (S)-2-(4-Benzoyloxy-benzylamino)-propionamide; 2-[4-(3-Chloro-benzoyloxy)-phenethyl]-amino-acetamide; 2-{[4-(3-Chloro-benzoyloxy)-benzyl]-methylamino}-acetamide; 2-(4-(3-Chloro-benzoyloxy)-benzylamino)-acetamide; (S)-(+)-2-[4-(2-Fluoro-benzoyloxy)-benzylamino]-propanamide; (S)-(+)-2-[4-(4-Fluoro-benzoyloxy)-benzylamino]-propanamide; (S)-(+)-2-[4-(3-Chloro-benzoyloxy)-benzylamino]-propanamide; (R)-(-)-2-[4-(3-Chloro-benzoyloxy)-benzylamino]-3-hydroxy-propanamide; (S)-(+)-2-{4-[2-(3-Fluorophenyl)-ethyl]-oxybenzyl}-amino-propanamide; 2-[4-(3-Fluoro-benzoyloxy)-benzylamino]-2-methyl-propanamide; and 2-[4-(3-Bromo-benzoyloxy)-benzylamino]-2-methyl-propanamide.
5. The method of claim 1, wherein the first composition is a MAO-B inhibitor.
6. The method of claim 5, wherein the first composition is selected from the group consisting of selegiline, rasagiline, lazabemide, and caroxazone.
7. The method of claim 1, wherein said second composition comprises at least one Parkinson's disease agent.
8. The method of claim 1, wherein said second composition comprises at least two Parkinson's Disease agents.
9. The method of claim 1, wherein said second composition comprises at least three Parkinson's Disease agents.
10. The method of claim 1, wherein said second composition comprises at least four Parkinson's Disease agents.

11. The method of claim 1, wherein said second composition comprises at least one dopamine agonist.
12. The method of claim 11, wherein said at least one dopamine agonist is selected from the group consisting of bromocriptine, cabergoline, lisuride, pergolide, ropinirole, apomorphine, sumanirole, rotigotine, talipexole, dihydroergocriptine, and pramipexole.
13. The method of claim 1, wherein said second composition comprises levodopa/PDI.
14. The method of claim 13, wherein said levodopa/PDI is selected from a group consisting of levodopa plus carbidopa (SINEMET®), levodopa plus controlled release carbidopa (SINEMET-CR®), levodopa plus benserazide (MADOPAR®), levodopa plus controlled release benserazide (MADOPAR-HBS).
15. The method of claim 1, wherein said second composition further comprises a catechol-O-methyltransferase inhibitor.
16. The method of claim 15, wherein said catechol-O-methyltransferase inhibitor is tolcapone or entacapone.
17. The method of claim 1, wherein said second composition further comprises amantidine.
18. The method of claim 1, wherein the amount of said first composition and the amount of said second composition are effective to reduce symptoms and to enable an observation of a reduction in symptoms.
19. A method of treating Parkinson's Disease, comprising administering to a patient in need thereof a pharmaceutical composition comprising safinamide and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient.
20. The method of claim 19, wherein the amount of said safinamide and said one or more Parkinson's Disease agents is effective to reduce symptoms and to enable an observation of a reduction in symptoms.
21. A method of treating Parkinson's Disease, comprising administering to a patient in need thereof a pharmaceutical composition comprising a safinamide derivative and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient.

22. The method of claim 21, wherein the amount of said safinamide derivative and said one or more Parkinson's Disease agents is effective to reduce symptoms and to enable an observation of a reduction in symptoms.
23. A method of treating Parkinson's Disease, comprising administering to a patient in need thereof a pharmaceutical composition comprising a MAO-B inhibitor and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient.
24. The method of claim 23, wherein the amount of said MAO-B inhibitor and said one or more Parkinson's Disease agents is effective to reduce symptoms and to enable an observation of a reduction in symptoms.
25. The method of any one of claims 19 - 24, wherein said one or more Parkinson's Disease agents comprise dopamine agonists.
26. The method of claim 25, wherein said dopamine agonists are selected from the group consisting of bromocriptine, pergolide, ropinirole, pramipexole, lisuride, cabergoline, apomorphine, sumanirole, rotigotine, talipexole and dihydroergocriptine.
27. The method of claim any one of claims 19 - 24, wherein said one or more Parkinson's Disease agents comprises levodopa/PDI.
28. The method of claim any one of claims 19 - 24, wherein said one or more Parkinson's Disease agents further comprises a catechol-O-methyltransferase inhibitor.
29. The method of claim any one of claims 19 - 24, wherein said one or more Parkinson's Disease agents further comprises amantidine.
30. A combination therapy for treating Parkinson's Disease, comprising administering to a subject having Parkinson's Disease a first composition comprising safinamide, a safinamide derivative, or a MAO-B inhibitor and a second composition comprising at least one Parkinson's Disease agent, such that said Parkinson's disease is treated or at least partially alleviated.
31. The combination therapy of claim 30, wherein the first composition is safinamide.
32. The combination therapy of claim 30, wherein the first composition is a safinamide derivative.

33. The combination therapy of claim 30, wherein the first composition is a MAO-B inhibitor.
34. The combination therapy of claim 33, wherein the first composition is selected from the group consisting of selegiline, rasagiline, lazabemide, and caroxazone.
35. The combination therapy of claim 30, wherein said second composition comprises at least two Parkinson's Disease agents.
36. The combination therapy of claim 30, wherein said second composition comprises at least three Parkinson's Disease agents.
37. The combination therapy of claim 30, wherein said second composition comprises at least four Parkinson's Disease agents.
38. The combination therapy of claim 30, wherein said second composition comprises at least one dopamine agonist.
39. The combination therapy of claim 38, wherein said at least one dopamine agonist is selected from the group consisting of bromocriptine, cabergoline, lisuride, pergolide, ropinirole, apomorphine, sumanirole, rotigotine, talipexole, dihydroergocriptine, and pramipexole.
40. The combination therapy of claim 30, wherein said second composition comprises levodopa/PDI.
41. The combination therapy of claim 30, wherein said second composition further comprises a catechol-O-methyltransferase inhibitor.
42. The combination therapy of claim 30, wherein said second composition further comprises amantidine.
43. The combination therapy of claim 30, wherein the amount of said first composition and the amount of said second composition are effective to reduce symptoms and to enable an observation of a reduction in symptoms.
44. The combination therapy of claim 31, wherein said safinamide administered at a dosage of about 0.5 to 10 mg/kg/day.
45. The combination therapy of claim 31, wherein said safinamide administered at a dosage of about 1 mg/kg/day.

46. A kit for treating a patient having Parkinson's Disease, comprising a therapeutically effective dose of a first composition comprising safinamide, a safinamide derivative, or a MAO-B inhibitor and a second composition comprising at least one Parkinson's Disease agent for treating or at least partially alleviating the symptoms of Parkinson's Disease, either in the same or separate packaging, and instructions for its use.
47. The kit of claim 46 wherein said second composition for treating Parkinson's Disease comprises at least one of a dopamine agonist, levodopa/PDI, a catechol-O-methyltransferase inhibitor and amantidine.
48. A pharmaceutical composition comprising safinamide and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient, in an effective amount to treat Parkinson's Disease.
49. A pharmaceutical composition comprising a safinamide derivative and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient, in an effective amount to treat Parkinson's Disease.
50. A pharmaceutical composition comprising a MAO-B inhibitor and one or more Parkinson's Disease agents, in an amount effective to treat said Parkinson's Disease in said patient, in an effective amount to treat Parkinson's Disease.
51. The pharmaceutical composition of any one of claims 48-50, wherein said one or more Parkinson's Disease agents comprises at least one of a dopamine agonist, levodopa/PDI, a catechol-O-methyltransferase inhibitor and amantidine.
52. The pharmaceutical composition of any one of claims 48-50, wherein the one or more Parkinson's Disease agents comprises a dopamine agonist in an effective amount to treat Parkinson's Disease.
53. The pharmaceutical composition of any one of claims 48-50, wherein one or more Parkinson's Disease agents comprises levodopa/PDI in an effective amount to treat Parkinson's Disease.
54. The pharmaceutical composition of any one of claims 48-50, wherein one or more Parkinson's Disease agents comprises levodopa/PDI and a catechol-O-methyltransferase inhibitor in an effective amount to treat Parkinson's Disease.

55. The pharmaceutical composition of any one of claims 48-50, wherein one or more Parkinson's Disease agents comprises levodopa/PDI, a catechol-O-methyltransferase inhibitor, and a dopamine agonist in an effective amount to treat Parkinson's Disease.
56. The pharmaceutical composition of any one of claims 48-50, wherein one or more Parkinson's Disease agents comprises levodopa/PDI, a catechol-O-methyltransferase inhibitor, a dopamine agonist and amantidine in an effective amount to treat Parkinson's Disease.